Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment
Sign Up to like & getrecommendations! Published in 2017 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-017-0258-x
Abstract: Background The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. Case presentation We describe an autoimmune polymyositis following a partial response to combination… read more here.
Keywords: tremelimumab durvalumab; treatment; polymyositis; polymyositis following ... See more keywords
Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0652
Abstract: Liver cancer is the third most common cause of cancer-related mortality worldwide, with over 780,000 deaths in 2018. About 90% of liver cancer cases are hepatocellular carcinoma (HCC), a prototype of inflammation-driven cancer, leading to… read more here.
Keywords: hepatocellular carcinoma; durvalumab treatment; cancer; tremelimumab durvalumab ... See more keywords